FDA hits ALX On­col­o­gy with par­tial clin­i­cal hold, cap­ping PhII stud­ies at 50 pa­tients while safe­ty check en­sues

5 years ago
FDA+

Up­dat­ed: #ASH20 Best of the Rest: Pfiz­er, Sang­amo launch a dura­bil­i­ty charge at Bio­Marin in hem A; The da­ta be­hind ...

5 years ago
R&D

Bay­er picks up off-the-shelf CAR-T ap­proach from Atara, spot­light­ing a Memo­r­i­al Sloan Ket­ter­ing break­through

5 years ago
Deals
Cell/Gene Tx

Backed by a $200M in­vest­ment from a Ko­re­an con­glom­er­ate, Vivek Ra­maswamy has qui­et­ly built a ‘moth­er ship’ for ...

5 years ago
Deals

#ASH20: Bain ex­ecs step in to po­si­tion a some­what bat­tered and bruised Sy­ros with a new clin­i­cal can­di­date and enough ...

5 years ago
Financing
R&D

#ASH20: Or­ca’s team show­cas­es their first cut of the da­ta on promis­ing cell pu­rifi­ca­tion work for HSCT

5 years ago
R&D

#ASH20 In a mul­ti­ple myelo­ma show­down, Re­gen­eron march­es out new PhI da­ta for its BC­MA bis­pe­cif­ic

5 years ago
R&D

#ASH20: As Bris­tol My­ers awaits FDA word, the CAR-T BC­MA lead­ers go head-to-head once again. This time, they're not ...

5 years ago
R&D
Cell/Gene Tx

#ASH20 Al­lo­gene's David Chang makes the case for an off-the-shelf CAR-T in the jam packed an­ti-BC­MA field

5 years ago
R&D
Cell/Gene Tx

#ASH20: Gilead­'s Kite reads out PhII da­ta to back CAR-T play­er Yescar­ta in a new in­di­ca­tion

5 years ago
R&D

#ASH20 Loxo and Eli Lil­ly show off PhI/II da­ta for their BTK in­hibitor in two blood can­cers

5 years ago
R&D

#ASH20: David Alt­shuler and the Ver­tex/CRISPR team hit a his­toric mile­stone in the hunt for a cu­ra­tive gene edit­ing ...

5 years ago
Cell/Gene Tx

A new RNA part­ner­ship hunts rare epilep­sies; Ab­b­Vie and I-Mab tack­le CD47

5 years ago
News Briefing

Zio­phar­m's ac­tivist dra­ma con­tin­ues as an­oth­er board mem­ber mem­ber re­signs. Is the end in sight?

5 years ago
Pharma

GSK vet Antony Blanc signs on to be­come Cure­Vac's CBO and CCO; Chris Ca­bell out, Paul Streck in as Are­na ...

5 years ago
Peer Review

A decade af­ter it first failed, a Shire-de­vel­oped Take­da an­tivi­ral ap­pears suc­cess­ful in Phase III

5 years ago
R&D

BioN­Tech chief Ugur Sahin gains star sta­tus in the ex­clu­sive Cov­il­lion­aire club

5 years ago
People
R&D

J&J guns for quick drug OK in lung can­cer niche, tak­ing the first step chal­leng­ing As­traZeneca in EGFR

5 years ago
FDA+

Lil­ly part­ners with Unit­ed­Health to con­duct 're­al-world' study for its Covid-19 an­ti­body bam­lanivimab

5 years ago
Coronavirus

Four biotechs hit Wall Street with up­sized IPOs, each rais­ing more than $20M over their goals

5 years ago
Financing

Sutro's con­tin­ued PhI da­ta read­outs in­di­cate im­prov­ing re­sponse in ovar­i­an can­cer. What's next?

5 years ago
R&D

Covid-19 roundup: Mod­er­na of­fers glimpse at dura­bil­i­ty da­ta; Bribery scan­dals mar Sino­vac's rep­u­ta­tion

5 years ago
Coronavirus

BioCryst wins ap­proval for HAE pill and charges half-a-mil­lion dol­lars, but will any­one take it?

5 years ago
Pharma
FDA+

KBI plans $150M fa­cil­i­ty in Re­search Tri­an­gle Park with mys­tery co-in­vestor

5 years ago
Outsourcing
First page Previous page 770771772773774775776 Next page Last page
A service from the Financial Times